Drug
BQ 788 clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 4
The University of Texas at Arlington (1) · University of Edinburgh (1) · Medical University of Vienna (1) · University of Southern Denmark (1)
Often tested with
Tested in the same studies.
cyclo(Trp-Asp-Pro-Val-Leu) (4) · Arginine (1) · Endothelin 1 (1)
Studies
Open first, then newest update. How each study uses BQ 788 is read from its arms, and is right about nine times in ten.
Testing it · 4
- The Effect of Endothelin and L-Arginine on Racial Differences in VasoconstrictionCompletedPhase 1The University of Texas at ArlingtonNCT03679780Written as BQ-788
- The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of EndothelinCompletedNot applicableUniversity of EdinburghNCT00745693Written as BQ-123 and BQ-788
- Insulin Stimulated Vasodilation in Patients With Type 2 DiabetesStatus unknownNot applicableUniversity of Southern DenmarkNCT04907838Written as BQ123 + BQ788
- Endothelin-Receptor Blockade in Coronary Heart DiseaseCompletedPhase 1Medical University of ViennaNCT00427232Written as BQ-123 and BQ-788
Codes
What other systems call BQ 788 · ClinicalTrials.gg INT003779
- MeSH (NLM) C086539BQ 788Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 44OLL8XEJ4BQ-788One source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C086539 | BQ 788 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 44OLL8XEJ4 | BQ-788 | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.